Search
User Avatar Login
The Defender
  • Explore The Defender
  • Categories
    • CHD.TV
  • Explore CHD.TV
  • Archive
    • Resources
  • Explore Our Resources
  • CHD Bookstore
  • CHD Films
  • eBooks
    • Community
  • Explore Advocacy
  • Community
  • Advocacy Help
    • Science
  • Explore the Science Section
  • Science Library
  • Vaccines
  • Electromagnetic Radiation
    • Legal Justice
  • Explore Litigation
  • Learn The Law
    • About Us
  • About Children’s Health Defense
  • More from CHD
    • Vax-Unvax: Let The Science Speak Home › Citations

    Chapter 10

    This is a listing of all citations in this chapter.

    31

    Francisco Tsz Tsun Lai et al., “Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine: A Case-Control Study,” Annals of Internal Medicine 175, no. 3 (2022); 362–370, doi:10.7326/M21-3700.

    32

    Dror Mevorach et al., “Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,” The New England Journal of Medicine 385, no. 23 (2021); 2140-2149, doi:10.1056/NEJMoa2109730.

    33

    Dror Mevorach et al., “Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,” The New England Journal of Medicine 385, no. 23 (2021); 2140-2149, doi:10.1056/NEJMoa2109730.

    34

    Dror Mevorach et al., “Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel,” The New England Journal of Medicine 385, no. 23 (2021); 2140-2149, doi:10.1056/NEJMoa2109730.

    35

    Marco Massari et al., “Postmarketing Active Surveillance of Myocarditis and Pericarditis Following Vaccination with COVID-19 mRNA Vaccines in Persons Aged 12 to 39 years in Italy: A Multi-Database, Self-Controlled Case Series Study,” PLoS Medicine 19, no. 7 (2022): e1004056, doi:10.1371/journal.pmed.1004056.

    36

    Marco Massari et al., “Postmarketing Active Surveillance of Myocarditis and Pericarditis Following Vaccination with COVID-19 mRNA Vaccines in Persons Aged 12 to 39 years in Italy: A Multi-Database, Self-Controlled Case Series Study,” PLoS Medicine 19, no. 7 (2022): e1004056, doi:10.1371/journal.pmed.1004056.

    37

    Kristin Goddard et al., Risk of Myocarditis and Pericarditis Following BNT162b2 and mRNA-1273 COVID-19 Vaccination,” Vaccine 40, no. 35 (2022): 5153–5159, doi:10.1016/j.vaccine.2022.07.007.

    38

    Kristin Goddard et al., Risk of Myocarditis and Pericarditis Following BNT162b2 and mRNA-1273 COVID-19 Vaccination,” Vaccine 40, no. 35 (2022): 5153–5159, doi:10.1016/j.vaccine.2022.07.007.

    39

    C.R. Simpson et al., “First-Dose ChAdOx1 and BNT162b2 COVID-19 Vaccines and Thrombocytopenic, Thromboembolic and Hemorrhagic Events in Scotland,” Nature Medicine 27, no. 7 (2021); 1290–1297, doi:10.1038/s41591-021-01408-4.

    40

    C.R. Simpson et al., “First-Dose ChAdOx1 and BNT162b2 COVID-19 Vaccines and Thrombocytopenic, Thromboembolic and Hemorrhagic Events in Scotland,” Nature Medicine 27, no. 7 (2021); 1290–1297, doi:10.1038/s41591-021-01408-4.

    41

    C.R. Simpson et al., “First-Dose ChAdOx1 and BNT162b2 COVID-19 Vaccines and Thrombocytopenic, Thromboembolic and Hemorrhagic Events in Scotland,” Nature Medicine 27, no. 7 (2021); 1290–1297, doi:10.1038/s41591-021-01408-4.

    42

    Jacob D. Berild et al., “Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries,” Journal of the American Medical Association Network Open 5, no. 6: e2217375, doi:10.1001/jamanetworkopen.2022.17375.

    43

    Jacob D. Berild et al., “Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries,” Journal of the American Medical Association Network Open 5, no. 6: e2217375, doi:10.1001/jamanetworkopen.2022.17375.

    44

    Erik Y.F. Wan et al., “Herpes Zoster Related Hospitalization after Inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 Vaccination: A Self-Controlled Case Series and Nested Case-Control Study,” The Lancet Regional Health: Western Pacific 21, no. 100393 (2022), doi:10.1016/j.lanwpc.2022.100393.

    45

    Erik Y.F. Wan et al., “Herpes Zoster Related Hospitalization after Inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 Vaccination: A Self-Controlled Case Series and Nested Case-Control Study,” The Lancet Regional Health: Western Pacific 21, no. 100393 (2022), doi:10.1016/j.lanwpc.2022.100393.

    46

    Erik Y.F. Wan et al., “Herpes Zoster Related Hospitalization after Inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 Vaccination: A Self-Controlled Case Series and Nested Case-Control Study,” The Lancet Regional Health: Western Pacific 21, no. 100393 (2022), doi:10.1016/j.lanwpc.2022.100393.

    47

    Yoav Yanir et al., “Association Between the BNT162b2 Messenger RNA COVID-19 Vaccine and the Risk of Sudden Sensorineural Hearing Loss,” Journal of the American Medical Association – Otolaryngology– Head and Neck Surgery 148, no. 4 (2022): 299-306, doi:10.1001/jamaoto.2021.4278.

    48

    Yoav Yanir et al., “Association Between the BNT162b2 Messenger RNA COVID-19 Vaccine and the Risk of Sudden Sensorineural Hearing Loss,” Journal of the American Medical Association – Otolaryngology– Head and Neck Surgery 148, no. 4 (2022): 299-306, doi:10.1001/jamaoto.2021.4278.

    49

    Diego Montano, “Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States,” Frontiers in Public Health 9 (2022): 756633, doi:10.3389/fpubh.2021.756633.

    50

    Diego Montano, “Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States,” Frontiers in Public Health 9 (2022): 756633, doi:10.3389/fpubh.2021.756633.

    51

    Diego Montano, “Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States,” Frontiers in Public Health 9 (2022): 756633, doi:10.3389/fpubh.2021.756633.

    52

    Hui-Lee Wong et al., “Surveillance of COVID-19 Vaccine Safety Among Elderly Persons Aged 65 Years and Older,” Vaccine 41, no. 2 (2023): 532–539, doi:10.1016/j.vaccine.2022.11.069.

    53

    Hui-Lee Wong et al., “Surveillance of COVID-19 Vaccine Safety Among Elderly Persons Aged 65 Years and Older,” Vaccine 41, no. 2 (2023): 532–539, doi:10.1016/j.vaccine.2022.11.069.

    54

    Joseph Fraiman et al., “Serious Adverse Events of Special Interest Following mRNA COVID-19 Vaccination in Randomized Trials in Adults,” Vaccine 40, no. 40 (2022): 5798–5805, doi:10.1016/j.vaccine.2022.08.036.

    55

    Joseph Fraiman et al., “Serious Adverse Events of Special Interest Following mRNA COVID-19 Vaccination in Randomized Trials in Adults,” Vaccine 40, no. 40 (2022): 5798–5805, doi:10.1016/j.vaccine.2022.08.036.

    56

    Joseph Fraiman et al., “Serious Adverse Events of Special Interest Following mRNA COVID-19 Vaccination in Randomized Trials in Adults,” Vaccine 40, no. 40 (2022): 5798–5805, doi:10.1016/j.vaccine.2022.08.036.

    57

    Joseph Fraiman et al., “Serious Adverse Events of Special Interest Following mRNA COVID-19 Vaccination in Randomized Trials in Adults,” Vaccine 40, no. 40 (2022): 5798–5805, doi:10.1016/j.vaccine.2022.08.036.

    58

    Kristin Goddard et al., Risk of Myocarditis and Pericarditis Following BNT162b2 and mRNA-1273 COVID-19 Vaccination,” Vaccine 40, no. 35 (2022): 5153–5159, doi:10.1016/j.vaccine.2022.07.007.

    59

    Francisco T. T. Lai et al., “Adverse Events of Special Interest Following the Use of BNT162b2 in Adolescents: A Population-Based Retrospective Cohort Study,” Emerging Microbes and Infections 11, no.1 (2022): 885–893, doi:10.1080/22221751.2022.2050952.

    60

    Marco Massari et al., “Postmarketing Active Surveillance of Myocarditis and Pericarditis Following Vaccination with COVID-19 mRNA Vaccines in Persons Aged 12 to 39 years in Italy: A Multi-Database, Self-Controlled Case Series Study,” PLoS Medicine 19, no. 7 (2022): e1004056, doi:10.1371/journal.pmed.1004056.